TY - JOUR
T1 - Nickel allergy is associated with a broad spectrum cytokine response
AU - De Graaf, Niels P.J.
AU - Roffel, Sanne
AU - Gibbs, Sue
AU - Kleverlaan, Cees J.
AU - Marta, Lopez Gonzalez
AU - Rustemeyer, Thomas
AU - Feilzer, Albert J.
AU - Bontkes, Hetty J.
AU - Lopez Gonzalez, Marta
N1 - Funding Information: We thank the NWO Domain TTO (formally known as STW) for funding this work. Publisher Copyright: © 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Background: Nickel-induced proliferation or cytokine release by peripheral blood mononuclear cells may be used for in vitro diagnosis of nickel allergy. Objectives: Aim of this study was to explore the nickel-specific cytokine profile to further elucidate the pathogenesis of nickel allergic contact dermatitis (ACD) and to identify potential new biomarkers for nickel ACD. Methods: Peripheral blood mononuclear cells from patients and controls were cultured with T-cell skewing cytokine cocktails and/or nickel. Cytokine and chemokine concentrations were assessed in culture supernatants using validated multiplex assays. Specific cytokine production was related to history of nickel allergy and patch-test results. Results: Twenty-one of the 33 analytes included in the analysis were associated with nickel allergy and included type1 (TNF-α, IFN-γ, TNF-β), type 2 (IL-3, IL-4, IL-5, IL-13), type 1/2 (IL-2, IL-10), type 9 (IL-9), type 17/1 (IL-17A[F], GM-CSF, IL-21) and type 22 (IL-22) derived cytokines as well as the T-cell/antigen presentation cell derived factors Thymus and activation regulated chemokine (TARC), IL-27 and IP-10. Receiver operator characteristics (ROC) analysis showed that IL-5 was the strongest biomarker for nickel allergy. Conclusions: A broad spectrum of 33 cytokines and chemokines is involved in the allergen-specific immune response in nickel allergic patients. IL-5 remains, next to the lymphocyte proliferation test, the strongest biomarker for nickel allergy.
AB - Background: Nickel-induced proliferation or cytokine release by peripheral blood mononuclear cells may be used for in vitro diagnosis of nickel allergy. Objectives: Aim of this study was to explore the nickel-specific cytokine profile to further elucidate the pathogenesis of nickel allergic contact dermatitis (ACD) and to identify potential new biomarkers for nickel ACD. Methods: Peripheral blood mononuclear cells from patients and controls were cultured with T-cell skewing cytokine cocktails and/or nickel. Cytokine and chemokine concentrations were assessed in culture supernatants using validated multiplex assays. Specific cytokine production was related to history of nickel allergy and patch-test results. Results: Twenty-one of the 33 analytes included in the analysis were associated with nickel allergy and included type1 (TNF-α, IFN-γ, TNF-β), type 2 (IL-3, IL-4, IL-5, IL-13), type 1/2 (IL-2, IL-10), type 9 (IL-9), type 17/1 (IL-17A[F], GM-CSF, IL-21) and type 22 (IL-22) derived cytokines as well as the T-cell/antigen presentation cell derived factors Thymus and activation regulated chemokine (TARC), IL-27 and IP-10. Receiver operator characteristics (ROC) analysis showed that IL-5 was the strongest biomarker for nickel allergy. Conclusions: A broad spectrum of 33 cytokines and chemokines is involved in the allergen-specific immune response in nickel allergic patients. IL-5 remains, next to the lymphocyte proliferation test, the strongest biomarker for nickel allergy.
KW - IL-5
KW - allergy
KW - contact dermatitis
KW - cytokines
KW - nickel
UR - http://www.scopus.com/inward/record.url?scp=85137603502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137603502&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/cod.14199
DO - https://doi.org/10.1111/cod.14199
M3 - Article
C2 - 36082421
SN - 0105-1873
VL - 88
SP - 10
EP - 17
JO - Contact dermatitis
JF - Contact dermatitis
IS - 1
ER -